Showing results (71-80 of 108) with videos related to
Sort By:
Pageof 11
Lung Cancer (Amsterdam, Netherlands)|May 18, 2025
A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020)Francesco Facchinetti, Andrea Camerini, Chiara Bennati, et al.European Journal of Cancer (Oxford, England : 1990)|May 16, 2022
Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registryAlessio Cortellini, Ramon Salazar, Alessandra Gennari, et al.Cell Reports. Medicine|April 29, 2026
IND-enabling safety and efficacy of RPESC-RPE-4W, an adult RPE progenitor cell therapy for dry age-related macular degenerationBrigitte L Arduini, Timothy A Blenkinsop, Michael Naimark, et al.Immunotherapy|February 25, 2020
Impact of influenza syndrome and flu vaccine on survival of cancer patients during immunotherapy in the INVIDIa studyMelissa Bersanelli, Sebastiano Buti, Giuseppe Luigi Banna, et al.Thoracic Cancer|December 23, 2021
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapyGiuseppe L Banna, Marcello Tiseo, Diego L Cortinovis, et al.Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.European Journal of Cancer (Oxford, England : 1990)|March 30, 2020
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance statusFrancesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri, et al.Journal for Immunotherapy of Cancer|November 30, 2022
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registriesAlessio Cortellini, Gino M Dettorre, Urania Dafni, et al.Tumori|May 4, 2026
Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to <i>KRAS</i> status: An Italian real-world studyAlessandro Leonetti, Vanessa Callegari, Fabiana Perrone, et al.European Journal of Cancer (Oxford, England : 1990)|March 15, 2024
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexedAlessandro Leonetti, Fabiana Perrone, Matteo Puntoni, et al.Pageof 11